Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChR
    (1)
  • Antibacterial
    (1)
  • Antibiotic
    (1)
  • DNA/RNA Synthesis
    (1)
  • Huntingtin
    (1)
  • Others
    (10)
Filter
Search Result
Results for "

systemically

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    15
    TargetMol | Inhibitors_Agonists
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
Elgodipine
T68060119413-55-7In house
Elgodipine significantly reduced the incidence and severity of exercise-induced angina pectoris systemically and was able to inhibit vascular smooth muscle proliferation through a mechanism independent of the expression of the transcription factors c-fos and c-jun. The Elgodipine-induced inhibition was voltage-dependent. Elgodipine is a potential compound for the treatment of angina pectoris.
  • $54
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Votoplam HCl
Votoplam HCl(2407849-89-0 Free base), PTC-518 HCl, PTC518 HCl
T79865L2407851-28-7
Votoplam HCl (PTC-518 HCl) is the hydrochloride form of Votoplam.Votoplam is a systemically acting gene splicing regulator that down-regulates the levels of huntingtin protein, which is primarily used to inhibit Huntington's disease (HD).
  • $296
In Stock
Size
QTY
Meclocycline sulfosalicylate salt
Meclutin, Mecloderm, Meclan Cream
T028173816-42-9
Meclocycline sulfosalicylate salt (Mecloderm), a tetracycline antibiotic, is used topically (i.e. for skin infections) as it is totally insoluble in water and may damage kidney and liver if given systemically.
  • $33
In Stock
Size
QTY
Betamethasone 17-Propionate
T2007535534-13-4
Betamethasone 17-Propionate is a compound used in the study of its effects on endotoxin-induced uveitis in rats, capable of inhibiting cellular infiltration into the aqueous humor when administered topically or systemically at certain doses. However, compared to some other compounds, its inhibitory effects are relatively weaker. When administered systemically, the dosage is 1mg kg. Additionally, in in vitro interleukin-8 (IL-8) release assays, Betamethasone 17-Propionate's suppression of IL-8 release from rat peritoneal exudate cells is less effective than that of betamethasone. Moreover, the concurrent addition of betamethasone dipropionate with Betamethasone 17-Propionate reduces the suppressive effects of betamethasone on cell infiltration and IL-1β gene expression.
  • $1,520
4-6 weeks
Size
QTY
AZD-9164
J3.232.015E, CHEMBL1921904, AZD9164, 977LWC4O5D
T2019421034978-04-5
AZD-9164, a muscarinic M3 receptor antagonist, is developed for potential use in treating chronic obstructive pulmonary disease. It is anticipated that AZD-9164 could surpass tiotropium's therapeutic index by enhancing both the extent and persistence of pulmonary function improvements, while not amplifying systemically-mediated adverse events.
  • Inquiry Price
10-14 weeks
Size
QTY
JNJ-40068782
JNJ 40068782
T27680950196-50-6
JNJ-40068782 is a potent, selective and systemically active positive allosteric modulator of the mGlu2 receptor.
  • $1,520
6-8 weeks
Size
QTY
LY 215490
LY215490,LY-215490
T27897150010-68-7
LY 215490 is a selective, competitive and systemically active antagonist of AMPA receptor. LY 215490 has neuroprotective effect against focal ischaemia in a model of permanent MCA occlusion in the rat.
  • $2,870
10-14 weeks
Size
QTY
LY 274614
T27909136109-04-1
LY 274614 is a structurally novel systemically active competitive NMDA receptor antagonist.
  • $2,420
10-14 weeks
Size
QTY
VU0453595
VU 0453595, VU-0453595
T291371432436-13-9
VU0453595 is a M1 positive allosteric modulator (PAM).
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Methylatropine (nitrate)
T3620452-88-0
Methylatropine is an antagonist of muscarinic acetylcholine receptors (IC50= <0.1 nM in a radioligand binding assay using isolated porcine brain membranes) and a derivative of atropine .1,2It reduces acetylcholine-induced decreases in blood pressure in rats when administered intravenously with an ED50value of 5.5 μg/kg.2Methylatropine reduces salivation, induces mydriasis, and increases heart rate in dogs.3 1.Schmeller, T., Sporer, F., Sauerwein, M., et al.Binding of tropane alkaloids to nicotinic and muscarinic acetylcholine receptorsPharmazie50(7)493-495(1995) 2.Brezenoff, H.E., Xiao, Y.-F., and Vargas, H.A comparison of the central and peripheral antimuscarinic effects of atropine and methylatropine injected systemically and into the cerebral ventriclesLife Sci.42(8)905-911(1988) 3.Albanus, L.Central and peripheral effects of anticholinergic compoundsActa Pharmacol. Toxicol. (Copenh)28(4)305-326(1970)
  • TBD
35 days
Size
QTY
MK-8245 Trifluoroacetate
T388441415559-41-9
MK-8245 trifluoroacetate is a phenoxy piperidine isoxazole derivative functioning as a potent, liver-targeting stearoyl-CoA desaturase (SCD) inhibitor, demonstrating significant anti-diabetic and anti-dyslipidemic effects. It showcases high specificity and efficacy against SCD1 across various species, with IC50 values of 1 nM for human SCD1 and 3 nM for both rat and mouse SCD1. MK-8245's mechanism includes a tetrazole acetic acid moiety that facilitates liver-targeting through OATPs recognition. Its inhibition potency in rat hepatocyte assays (IC50 of 68 nM) surpasses that in HepG2 cell assays devoid of active OATPs (IC50 of ~1 μM), highlighting its liver specificity. Moreover, MK-8245 exhibits over 100,000-fold selectivity against Δ-5 and Δ-6 desaturases in comparative assays. In vivo studies reveal MK-8245's preferential liver distribution in mice, rats, dogs, and rhesus monkeys, underscoring its potential for minimizing adverse effects in non-target tissues. Additionally, its administration in eDIO mice before glucose challenges significantly improves glucose clearance, indicating its therapeutic promise in diabetes management.
  • Inquiry Price
Size
QTY
Clocinnamox mesylate
C-CAM,NIH 10443
T41184117332-69-1
Clocinnamox mesylate is a systemically active, irreversibleμ-opioid receptor antagonist (apparent Kivalues are 0.7, 1.9 and 5.7 nM for mouseμ,δandκreceptors respectively).
  • $970
Backorder
Size
QTY
AS1940477
T68321928344-12-1
AS1940477 is p38 MAPK inhibitor. AS1940477 inhibited the enzymatic activity of recombinant p38α and β isoforms but showed no effect against other 100 protein kinases including p38γ and δ isoforms. In human peripheral blood mononuclear cells, AS1940477 inhibited lipopolysaccharide (LPS)- or phytohemagglutinin A (PHA)-induced production of proinflammatory cytokines, including TNFα, IL-1β, and IL-6 at low concentrations (LPS TNFα, IC(50)=0.45n M; PHA TNFα, IC(50)=0.40 nM). In addition, equivalent concentrations of AS1940477 that inhibited cytokine production also inhibited TNFα- and IL-1 β-induced production of IL-6, PGE(2), and MMP-3 in human synovial stromal cells. AS1940477 was also found to potently inhibit TNF production in whole blood (IC(50)=12 nM) and effectively inhibited TNFα production induced by systemically administered LPS in rats at less than 0.1mg kg (ED(50)=0.053 mg kg) with an anti-inflammatory effect lasting for 20h after oral administration. Overall, this stu......
  • $2,870
10-14 weeks
Size
QTY
LY2934747
T706191448707-43-4
LY2934747 is a novel, potent, and systemically bioavailable mGlu2 3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo.
  • $3,170
10-14 weeks
Size
QTY
Clencyclohexerol
T71931157877-79-7
Clencyclohexerol is an analog of clenbuterol. β-Adrenoceptor agonists, including clenbuterol, modulate protein synthesis and degradation and have therapeutic potential in muscle wasting disorders. β-adrenoceptor agonists have deleterious cardiovascular side effects when used systemically and at high concentrations.
  • TBD
35 days
Size
QTY